HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: US$313mn One-Way, Four Names with Double-Impacts

Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Multiple Changes to Expectations; US$481mn One-Way

Quiddity Leaderboard ChiNext & ChiNext 50 Jun 24: Bullish Names Outperform Bearish Names Again

Wuxi Biologics (2269.HK) - The Latest Updates Related to 2024 Performance Worth the Attention

WuXi AppTec (2359.HK/603259.CH) - Behind the Plunge Is a War

Haier Group to Buy $1.8B Stake in Shanghai RAAS from Grifols – A New Chapter Begins

Escalation of Israel-Hamas War - Here's How Investors Should Position Themselves in Dramatic Changes

Equity Bottom-Up

CSPC Innovation Pharmaceutical-A / Equity Bottom-Up

CSPC Innovation Pharmaceutical-A (300765 CH)

<ul>
<li>If there’s ultimately substantial negative policies in the field of biopharmaceuticals between China and US, APIs will be the segment with the highest risk. But CXO would also be affected.</li>
<li>Now we have entered the harvest period after the previous peak of financing round in China's biotech industry, which has become a concentrated "peach picking period" for foreign pharmaceutical enterprises.</li>
<li>Considering the low market sentiment, we’re cautious on companies with high valuation elasticity before they come up with convincing products. So, we don’t recommend investors rush to bottom-fish CSPC Innovation.</li>
</ul>


If there’s ultimately substantial negative policies in the field of biopharmaceuticals between China and US, APIs will be the segment with the highest risk. But CXO would also be affected.
Now we have entered the harvest period after the previous peak of financing round in China's biotech industry, which has become a concentrated "peach picking period" for foreign pharmaceutical enterprises.
Considering the low market sentiment, we’re cautious on companies with high valuation elasticity before they come up with convincing products. So, we don’t recommend investors rush to bottom-fish CSPC Innovation.


China Healthcare Weekly (Feb.2) - US Strike on China CXOs, CSPC Innovation, Peach Picking Period